Furoscix Injection Kit Prior Authorization Criteria
Customize your policy alerts
Sign up for all medimpact policy alerts
Know when medimpact releases new policies or updates existing guidance.
Monitor payer policy activity
Defines Kentucky Medicaid prior authorization requirements for Furoscix Injection Kit for outpatient short-term parenteral diuresis, affecting prescribers, pharmacy providers, and Kentucky Medicaid members.
Medicaid DMS will implement clinical prior authorization criteria for Furoscix Injection Kit effective May 1, 2026.
Initial approval duration set to 3 months and renewal duration set to 3 months.
Quantity limit of 8 kits per 30 days established.
Coverage Criteria for Furoscix Injection Kit
inv-01: Initial Therapy
Covered when ALL of the following are met for initial therapy:
Attestation must include all listed elements
inv-02: Renewal Therapy
Renewal approval requires ALL of the following:
Coverage is not approved when the requested dosing exceeds the FDA‑approved dose for Furoscix or when the patient does not meet the package insert minimum age and weight requirements. Requests lacking required clinical documentation and prescriber attestations (including baseline labs and the attestation elements listed in the policy) may also be denied.
Furoscix coverage is limited to use as short‑term, episodic outpatient parenteral diuresis for patients with edema/volume overload related to chronic heart failure or chronic kidney disease, as specified in the criteria. Use of Furoscix for other indications or for ongoing/chronic inpatient diuresis is outside the scope of this policy and is not supported.
Initial Authorization Requirements
inv-12: Initial Therapy
Initial authorization requirements:
Renewal / Continuation Requirements
inv-13: Renewal/Continuation Therapy
Renewal rules for continued coverage:
Provider Requirements, Documentation, and Denial Triggers
Prior authorization required — effective 05/01/2026; 3‑month approvals
Prior authorization is required for Furoscix Injection Kit for Kentucky Medicaid members beginning May 1, 2026. Initial approvals are for 3 months; renewals are for 3 months contingent on meeting renewal criteria.
Step therapy — document optimization or clinical rationale
Approval requires documentation of ONE of the following: recent optimization of oral diuretic strategy with insufficient response, intolerance, or contraindication; OR a clinical rationale why alternative loop‑diuretic formulations/settings (e.g., higher‑dose oral, clinic/infusion‑center IV) are not suitable for this episode.
Required documentation and prescriber attestations
Include clinical and attestation elements with the PA request: diagnosis of CHF or CKD with current edema/volume overload; prescriber specialty (or consultation) with cardiology/nephrology or relevant specialist; prescriber attestations (hemodynamic stability; candidate for outpatient diuresis; short‑term episodic use; plan to transition back to oral loop diuretics; documented patient/caregiver home management plan); baseline renal function and electrolytes obtained prior to first dose; confirmation of package‑insert age/weight and that requested dose does not exceed FDA‑approved dosing.
- Diagnosis and current edema/volume overload
- Specialist prescriber or documented consultation
- Prescriber attestation with all listed elements
- Baseline labs: serum creatinine/eGFR, BUN, sodium, potassium, bicarbonate
- Age/weight per package insert and dose within FDA limits
Denial triggers — missing criteria or documentation
Requests may be denied if required criteria or documentation are missing, including absence of a qualifying CHF or CKD diagnosis with edema requiring parenteral diuresis; lack of specialist prescribing/consultation; missing prescriber attestations; no documentation of optimization of oral diuretics or clinical rationale for alternatives; missing baseline or recent labs; or if requested dose/age/weight fall outside package‑insert/FDA limits.
- No diagnosis of CHF or CKD with edema requiring parenteral diuresis
- Missing specialist prescriber or consultation
- Absent prescriber attestations (hemodynamic stability, outpatient candidacy, short‑term use, transition plan, home management)
- No documentation of oral diuretic optimization or clinical rationale for alternatives
- Missing baseline or renewal labs
- Requested dose exceeds FDA‑approved dosing or patient below package‑insert age/weight
Step Therapy / Alternatives
| Requirement | Documentation to submit |
|---|---|
| Documentation that the patient had recent optimization of oral diuretic therapy with insufficient response, intolerance, or contraindication | Clinical notes or progress documentation showing attempted oral diuretic adjustments and reasons for failure (e.g., lack of diuresis, adverse effects, contraindication) |
| OR clinical rationale why alternative loop‑diuretic formulations/settings are unsuitable (e.g., higher‑dose oral therapy not appropriate, IV diuresis in clinic/infusion center not feasible) | Provider narrative explaining why alternative formulations or settings are not appropriate for this episode (safety, access, intolerance, or logistic reasons) |
| Baseline and recent laboratory documentation as applicable (serum creatinine/eGFR, BUN, sodium, potassium, bicarbonate) | Laboratory results obtained prior to first dose and within the current authorization period for renewals per policy requirements |
Quantity Limits and Dispensing Rules
Site of Care / Intended Setting
Site of care — outpatient/home administration only
Use is intended for outpatient/home administration for patients who are candidates for diuresis outside the hospital and who have a documented home management plan. Ensure patient/caregiver home management and outpatient candidacy are documented in the request.
- Documented patient/caregiver home management plan (e.g., home weight monitoring, plan for escalation of care)
- Attestation patient is a candidate for diuresis outside of the hospital
Definitions and Required Baseline Data
Background
Furoscix (subcutaneous furosemide) is intended to provide short‑term, outpatient parenteral diuresis for patients with edema or volume overload related to Chronic Heart Failure (CHF) or Chronic Kidney Disease (CKD) when oral diuretic therapy is insufficient or unsuitable. The policy requires baseline and ongoing monitoring of renal function and electrolytes (e.g., serum creatinine/eGFR, BUN, sodium, potassium, bicarbonate) and clinician attestations that the patient is hemodynamically stable, a candidate for outpatient diuresis, being treated for short‑term episodic decongestion, has a plan to transition back to oral loop diuretics, and has a documented home management plan.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.